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The pathogenesis of inflammatory bowel disease (IBD) is incompletely understood but 
results from a dysregulated intestinal immune response to the luminal microbiota. CD4+ 
T-cells mediate tissue injury in the IBD-associated immune response. Dendritic cells 
(DC) generate primary T-cell responses and mediate intestinal immune tolerance to 
prevent overt inflammation in response to the gut microbiota. However, most 
information regarding function of intestinal DC has come from mouse models and 
information in humans is scarce. We show here that intestinal DC subsets are skewed 
in ulcerative colitis (UC) in humans, with a loss of CD103+ lymph-node homing DC; this 
intestinal DC subset preferentially generates regulatory T-cells in mice. We show 
infiltrates of DC negative for myeloid marker CD11c, with enhanced expression of Toll-
like receptors (TLRs) for bacterial recognition. Following mixed leucocyte reaction, DC 
from the inflamed UC colon had an enhanced ability to generate gut-specific CD4+ T-
cells with enhanced production of IL-4, but a loss of IFNγ and IL-22 production. 
Conditioning intestinal DC with probiotic strain Lactobacillus casei Shirota in UC partially 
restored their normal function indicated by reduced TLR2/4 expression and restoration 
of their ability to imprint homing molecules on T-cells and to generate IL-22 production 
by stimulated T-cells. This study suggests that T-cell dysfunction in UC is driven by DC. 
T-cell responses can be manipulated indirectly via effects of bacterial conditioning on 
gut DC, with implications for immunomodulatory effects of the commensal microbiota in 









































































Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative 
colitis (UC), is characterized by chronic relapsing and remitting intestinal inflammation 
(1;26;30;59). The pathogenesis of IBD is incompletely understood but is thought to 
result from a dysregulated response of the intestinal immune system to components of 
the luminal microbiota, and breakdown of immune tolerance in individuals who are 
genetically predisposed to the disease. These processes lead to “inappropriate” 
activation of mucosal T-cells and production of inflammatory mediators (3;5;42;51). 
CD4+ T-cells are major players in the IBD-associated immune response; T-cell derived 
cytokines, either directly or indirectly, mediate intestinal tissue injury (26;52). 
 
Dendritic cells (DC) are specialized antigen-presenting cells (APC) that are unique in 
their ability to generate primary, antigen-specific T-cell responses (4;50). DC also 
determine whether T-cell responses generated are tolerogenic or immunogenic (4;19). 
In particular, intestinal DC maintain the delicate balance in the gut between 
immunogenicity against invading pathogens and tolerance of the commensal microbiota 
(reviewed in (12;33;45). Intestinal DC from the gut lamina propria (LP) recognize and 
respond to bacteria and bacterial products from the gut lumen, and transport bacterial 
antigens to mesenteric lymph nodes (MLN (31;57)), where they subsequently generate 
antigen-specific T-cell responses. Given their ability to drive primary T-cell responses, 
and bacterial sampling properties, intestinal DC play a critical role in the pathology of 
IBD, a T-cell dominated disease. Activated DC accumulate throughout the intestinal LP 
and MLN in mouse models of colitis (27;29;53), and murine models also provide strong 
evidence that interactions between the intestinal microbiota and intestinal DC are 
essential for IBD pathogenesis (24;40). Human studies have shown an increase in DC 
number within inflamed IBD tissue (25;55), and enhanced expression of bacterial 
recognition receptors on DC in IBD, providing a potential mechanism of inappropriate 
recognition of bacterial antigens from the gut lumen (15). However, there is currently 
little information available regarding mechanisms by which intestinal DC may cause T-
cell pathology in IBD.  
 
Intestinal DC in the steady state are generally hyporesponsive to TLR ligation (11) and 
maintain immune tolerance in the gut by generation of regulatory T-cell responses 
towards food antigens and commensal bacteria, preventing unnecessary inflammation 
and hypersensitivity (10;11;58). In mice, CD103 (integrin αE)
+ DC migrate to MLN in 
afferent lymph (44); in the steady state this constitutive migration generates tolerogenic 
T-cell responses against harmless luminal antigens and establishes oral tolerance 
(11;58). Furthermore, murine CD103+ DC specialize to imprint gut-homing markers on 
regulatory T-cell subsets (22). DC imprint specific homing and migratory properties on 
T-cells that they stimulate, to localize immune responses to specific tissues; the first 
studies on murine gut DC imprinting capacity demonstrated these DC generated T-cells 
expressing the gut-homing markers α4β7 and CCR9 (23;37;49). Dysregulated 
lymphocyte trafficking has been reported in both CD and UC, with enhanced 
lymphocyte expression of gut-homing molecule α4β7 (2;9;16;17). Mechanisms of how 
this occurs are unknown, but are likely to involve DC stimulation of T-cells.  































































Interactions between the host and the microbiota play a crucial role in maintaining 
mucosal immune homeostasis in the steady state (reviewed in (47)), as well as driving 
pathology in an inflammatory setting (51). Bacterial genera that can usually be found in 
the normal commensal microbiota include Lactobacillus and Bifidobacterium species; 
certain strains of these bacteria have been classed as probiotics because their 
consumption is associated with health benefits, usually mediated via the gut 
(13;14;28;36;43). The effects of intestinal commensal bacteria on gut DC which are so 
pivotal in early bacterial recognition and shaping T-cell responses are likely to be central 
to the maintenance of intestinal immune homeostasis. Indeed, reduced intestinal 
bacterial diversity and increased amounts of disease-associated bacterial strains have 
been reported in IBD (46).  
 
 
A critical barrier in the development of targeted immunomodulatory therapies in IBD 
stems from a lack of understanding how dysregulated T-cell responses directed against 
the gut microbiota are initiated in IBD. The aims of this study were to characterise 
human intestinal DC in healthy controls compared to UC patients, to determine whether 
alterations occur in DC ability to generate T-cell responses in IBD and to condition 
intestinal DC with probiotic strain Lactobacillus casei Shirota (LcS) to determine any 
knock on effects on T-cells. We hypothesised that DC from the UC colon drive 
dysregulated T-cell responses, and that bacterial conditioning of gut DC can shape their 
function and ability to prime specific T-cell responses, with implications in vivo being 





































































MATERIALS AND METHODS 
 
Tissues and cells 
 
Colonic biopsies  
 
Biopsies were obtained at colonoscopy, following informed consent. Patient groups 
included active UC patients (biopsies taken from inflamed and non-inflamed areas for 
phenotyping experiments) and healthy controls. Healthy controls had macroscopically 
and histologically normal intestines, and were undergoing colonoscopy for rectal 
bleeding or because of a family history of colorectal cancer. Diagnosis for patients with 
active UC was made according to clinical parameters, radiographic studies, endoscopic 
and histological criteria. Disease activity for UC was assessed using the UC disease 
activity index (UCDAI) with active UC patients having a UCDAI score >4. Patients were 
treatment naive or on stable therapy with 5-aminosalicylic acid and/or azathioprine. No 
patients were on corticosteroids or anti-TNF therapies. Biopsies were collected in ice-
chilled complete medium. 
 
Intestinal dendritic cells  
 
Total lamina propria cells were obtained from biopsy tissue by a cell migration/”walkout” 
method during 20 hour incubation of biopsies (37ºC, 5%CO2, high humidity) in complete 
medium (RPMI 1640 (Dutch modification; Sigma-Aldrich, Dorset, UK) supplemented 
with 10% FCS, 100µml-1 penicillin, 100µgml-1 streptomycin and 20mM L-glutamine), 
following removal of mucus and epithelial cells via DTT/EDTA incubation, as previously 
described4,i. DC were identified as HLA-DR+lineage cocktail- (HLA-DR+CD3-CD14-
CD16-CD19-CD34-) by flow cytometry and analysed for surface expression of molecules 
of interest or enriched for T-cell stimulation assays as described below.   
 
 
LcS conditioning of intestinal dendritic cells 
 
Gut biopsies were incubated for 20 hours for the walkout method following DTT/EDTA 
treatment, in complete medium with or without 1x107CFU/ml heat-killed LcS (dose had 
been previous optimised using human blood DC (34)). DC were then identified as HLA-
DR+lineage cocktail- by flow cytometry or enriched by centrifugation (600g, 15min at RT) 
over NycoprepTM and used for T-cell stimulation. These enriched DC have been 
characterised as functional colonic DC (7).   
 
 
Enrichment of T-cells for DC and T-cell co-culture 
 
Peripheral blood mononuclear cells obtained from a healthy donor were suspended in 
MiniMACS buffer (PBS containing 0.5% BSA and 2mM EDTA) and T-cells were 
enriched by depletion of CD14+, CD19+ and HLA-DR+ cells with immunomagnetic beads 
(Miltenyi Biotech, Bisley, UK) following manufacturer’s instructions.  
































































T-cell proliferation assay 
 
Carboxyfluorescein diacetate succinimidyl ester (CFSE, Invitrogen Ltd, UK) labelled 
CD4+ naive T-cells (4x105/well) were incubated for 5 days in U-bottomed 96-well 
microtitre plates with enriched intestinal allogeneic DC at 1%, 2% and 3%, in a mixed 
leucocyte reaction (MLR). Cells were recovered and CFSElo proliferating cells were 
identified and quantified by flow cytometry. T-cells were also cultured in the absence of 





Monoclonal antibodies with the following specificities and conjugations were used: 
CD40-FITC (LOB7/6), TLR2-FITC (TLR2.3), TLR4-FITC (HTA125), CD3-RPE-Cy5 
(UCHT1) and CD19-RPE-Cy5 (SJ25-C1) were purchased from AbD Serotec (Oxford, 
UK); CD80-FITC (L307.4), CD83-PE (HB15e), CD86-FITC (24F), CD103-FITC (Ber-
ACT8), β7-integrin-PE (FIB504), CLA-biotin (HECA-452), IL-10-APC (JES3-19F1), IL-4-
PeCy7 (8D4-8), IFNγ-APC (25723.11), IL-17A-PE (SCPL1362), FoxP3-PE (259D/C7), 
HLA-DR-APC (G46-6), CD16-PeCy5 (3G8), CD14-PeCy5 (M5E2) and CD34-PeCy5 
(581) were purchased from BD Biosciences (Oxford, UK); CCR7-PE (150503), CCR9-
PE (112509), CCR4-APC (205410) and latent TGFβ1-PE (IC388P) were purchased 
from R&D systems (Abingdon, UK); CD11c-FITC (KB90) was purchased from Dako 
(Ely, UK); IL-22-PeCy7 (22URTI) was purchased from eBioscience (San Diego, USA). 
Appropriate isotype-matched control antibodies were purchased from the same 
manufacturers. After staining, cells were fixed with 1% paraformaldehyde in 0.85% 
saline and stored at 4°C prior to acquision on the flow cytometer, within 48 hours.  
 
 
Flow cytometry and data analysis 
 
Data were acquired on a FACSCanto II cytometer (BD Biosciences) and analysed using 
WinList 5.0 software (Verity, ME, US). Gating strategies to determine proportions of 
positive cells were determined by comparison to the appropriate isotype-matched 





The intracellular cytokine production by stimulated T-cells post-MLR was measured 
using superenhanced Dmax normalised subtraction upon data analysis following 



































































Data are presented as mean and standard errors (with representative histograms/dot 
plots). Two-way repeated measures ANOVA, and two-tailed paired t-tests were applied 
as stated in the figure legends. In the case of multiple comparisons, subsequent ad hoc 
Bonferroni correction was applied. P<0.05 was considered statistically significant.  
  































































Alterations in DC subsets in the UC colon 
Loss of “regulatory” CD103+CCR7+ DC in UC 
 
Intestinal DC were isolated and characterised from healthy controls and from patients 
with active UC (biopsies were taken from both inflamed and non-inflamed colon in UC 
for phenotyping purposes). Human intestinal DC were identified as HLA-DR+/lineage 
cocktail (CD3/CD14/CD16/CD19/CD34)- cells by flow cytometry (figure 1a). In mice, 
CD103+ DC are migratory DC that travel to mesenteric lymph nodes (MLN) to prime gut-
homing, regulatory T-cells; these cells are essential for maintenance of mucosal 
immune homeostasis (11). In this study, the UC colon contained a lower proportion of 
DC co-expressing CD103 with lymph node-homing marker CCR7 compared to the 
healthy colon; a greater loss was observed in the inflamed UC colon compared to the 
non-inflamed UC colon (figure 1b). There was a loss of total CD103+ DC from the 
inflamed UC colon but no differences in total CCR7+ DC between UC patients and 
healthy controls. Proportions of CD103+CCR7- DC were also comparable between 
healthy controls and UC patients (data not shown).  
 
Enhanced proportions of non-myeloid CD11c- DC in UC 
 
Although the majority of DC in the healthy human colon were CD11c+ (myeloid) cells, 
there was an enhanced proportion of CD11c- (non-myeloid) DC in the inflamed UC 
colon (figure 1c).  
 
Alterations in DC phenotype in the UC colon 
The acquisition of antigens by DC is enabled in part through their rich supply of pattern 
recognition receptors such as Toll-like receptors (TLRs). Bacterial recognition by TLRs 
on DC is one of the major pathways by which intestinal DC sample intestinal antigens. 
TLRs 2 and 4 were aberrantly expressed on intestinal DC in UC compared with healthy 
controls; in the latter, expression of both TLR2 and TLR4 was minimal. Expression of 
TLRs 2 and 4 was enhanced on DC from inflamed areas of the gut mucosa in UC, 
compared to healthy control DC (figure 2). These data support previous studies in which 
it has been proposed that enhanced expression of TLRs on intestinal DC in IBD may 
contribute to the dysregulated intestinal immune response to bacterial luminal 
components (15). 
 
LcS partially restored normal levels of TLR2/4 expression on gut DC from inflamed 
tissue in UC 
 
Colonic biopsies from healthy controls and patients with active UC (biopsies from both 
inflamed and non-inflamed areas for phenotyping purposes) were cultured in vitro for 20 
hours in in the presence of 1x107 CFU/ml heat-killed Lactobacillus casei Shirota (LcS; 
concentration previously optimised) or complete medium only. Conditioning gut DC from 
the inflamed UC colon with LcS partially restored the normal low levels of TLR2/4 






























































expression observed on healthy gut DC, by significantly reducing expression of both 
TLR2 and TLR4 (figure 2). LcS did not affect proportions of DC subsets and there were 
no significant effects of LcS conditioning of healthy gut DC on expression of TLRs 2 and 
4 (data not shown); however this may be due to the low baseline level of expression of 
these receptors on human gut DC in healthy controls.  LcS conditioning did not alter 
proportions of gut DC expressing CD103, CCR7 or CD11c in either UC patients or 
healthy controls (data not shown).  
 
 
Reduced stimulatory capacity for T-cells by intestinal DC in UC 
Intestinal DC were isolated and characterised from healthy controls and from patients 
with active UC (biopsies from inflamed colon only) and enriched for DC (7) prior to 5-
day co-culture with CD4+  naive allogeneic T-cells (pre-sorted) from a separate, healthy 
blood donor in a mixed leucocyte reaction (MLR). Dividing T-cells were identified by flow 
cytometry post-culture as CFSElo T-cells (figure 3a). Following MLR, dose-dependent T-
cell proliferative responses were generated by gut DC from both healthy controls and 
UC patients (figure 3b). Intestinal DC from UC patients exhibited a restricted stimulatory 




LcS partially restored function of DC from inflamed tissue in UC: stimulation of T-cells 
 
For MLR experiments, DC (inflamed areas only in UC patients) were pre-conditioned 
with LcS, washed and then co-cultured with T-cells so that LcS cells were not in direct 
contact with T-cells; therefore effects of LcS observed on T-cells would be mediated via 
DC. Pre-conditioning UC-DC with LcS significantly enhanced their stimulatory capacity 




Intestinal DC imprint aberrant homing properties on T-cells in UC 
Following MLR, the homing profile of stimulated T-cells, imprinted by DC, was assessed 
via surface staining for a variety of gut- and skin-specific homing markers. Gut DC in UC 
induced enhanced expression of gut-homing marker CCR9 on stimulated T-cells, 
compared to their healthy control counterparts. Expression of gut-homing marker β7 
integrin was expressed on the majority of dividing T-cells and proportions of β7+ T-cells 
were unchanged following stimulation with UC-DC compared to control DC (figure 4a). 
Levels of β7 expression measured via mean fluorescence intensity (MFI) were also 
unchanged between UC-DC and control DC (data not shown). Gut DC in UC induced 
reduced expression of skin-homing markers CLA and CCR4 on stimulated T-cells, 
compared to their healthy control counterparts (figure 4b).  
 






























































LcS partially restored function of DC from inflamed tissue in UC: imprinting homing 
properties on T-cells 
LcS treatment of gut DC in UC restored their ability to imprint skin-homing marker CLA 
on T-cells that they stimulated (figure 4b). However, there were no effects of LcS 
treatment on DC ability to imprint CCR4, CCR9 or β7 (figures 4a and 4b).  
 
Intestinal DC skew the cytokine profile of stimulated T-cells in UC 
Gut DC in UC induced more IL-4 (Th2 cytokine) production, but less IFNγ (Th1 
cytokine) and less IL-22 production from T-cells that they stimulated, compared to 
healthy control DC. Levels of IL-10, TGFβ and IL-17A produced by T-cells were 
unchanged regardless of type of DC stimulation (figure 5a). 
 
LcS partially restored function of DC from inflamed tissue in UC: cytokine production by 
T-cells 
In a new series of paired experiments, LcS treatment of gut DC in UC restored their 
ability to induce IL-22 production by T-cells that they stimulated (figure 5b). However, 
there were no effects of LcS treatment on DC ability to induce IFNγ or IL-4 production 
by T-cells (or other cytokines measured; figure 5b).  
  
































































We demonstrate in this study that in UC, human intestinal DC drive aberrant cytokine 
production by T-cells in vitro with an enhanced capacity to imprint gut-specific homing 
properties on T-cells, skewing gut-specific T-cell responses towards a Th2 type 
response. Inappropriate activation of mucosal CD4+ T-cells in IBD leads to production of 
T-cell cytokines, which either directly or indirectly, mediate intestinal tissue injury 
(26;52). A critical barrier in the development of targeted immunomodulatory therapies in 
IBD stems from a lack of understanding of how dysregulated T-cell responses directed 
against the gut microbiota are initiated in IBD. Intestinal DC recognize and respond to 
bacteria and bacterial products from the gut lumen and transport bacterial antigens to 
the MLN (31;57) to generate antigen-specific T-cell responses, strongly suggesting 
inappropriate T-cell responses to the gut microbiota in IBD are mediated by DC. 
However, constitutive migration of murine CD103+ DC to MLN generates tolerogenic T-
cell responses against harmless luminal antigens and establishes oral tolerance 
(11;21;58). This study demonstrates a loss of CD103+ lymph-node homing DC in the 
UC gut, and suggests that skewing of DC subsets contributes to T-cell mediated 
pathogenesis in UC. In mice, this DC subset is responsible for generating regulatory T-
cell responses and inducing B-cell class switching from IgM- to IgA-producing B-cells, a 
process critical for intestinal immune homeostasis (38). Furthermore, we demonstrate 
that probiotic strain LcS partially restores the normal function of intestinal DC in UC, 
suggesting that commensal and/or probiotic lactobacilli may directly modulate intestinal 
DC function to maintain intestinal immune homeostasis.  These data also suggest that 
the reported beneficial effects of probiotic strains in IBD (13;14;28;36;43) may be 
mediated by gut DC due to their bacterial sampling function (18).  
 
Gut DC play a central role in immune hom ostasis in the gut (10) and exhibit 
tolerogenic properties (15;45) that are likely to be due to the high antigenic load at 
intestinal sites, including food antigens and the commensal microbiota. However, these 
data provide a role for CD11c- non-myeloid DC in UC pathogenesis. The infiltration of 
CD11c- DC into inflamed tissue in the UC colon is likely to contribute to the reduced T-
cell stimulatory capacity of the total intestinal DC population in UC, given the restricted 
stimulatory capacity of CD11c- DC compared with their CD11c+ (myeloid) counterparts 
(39). The CD11c- DC in the UC gut may represent plasmacytoid DC (pDC), which have 
been reported to be increased in human gut mucosa MLN in IBD (6)  and which are a 
source of pro-inflammatory cytokines in the intestinal gut mucosa (20). Some CD11c- 
DC may also represent CD56+CD11c- DC, which have previously been reported to 
infiltrate both inflamed and non-inflamed areas of the UC gut (39). Further studies will 
determine the subpopulations and functions of these CD11c- DC in UC. The enhanced 
TLR expression on total intestinal DC in UC have implications in enhanced ability to 
recognize and respond to bacterial antigens and potentially generating inappropriate T-
cell responses to the gut microbiota.  
 
The enhanced ability of gut DC in UC to imprint gut-homing markers on T-cells, taken 
with the reduced capacity to imprint skin-homing markers reflects the dysregulated 
function of intestinal DC in UC, and may partially account for the increased infiltrates of 






























































gut-homing T-cells at sites of inflammation in UC (16;17). Indeed, we have previously 
demonstrated fresh gut T-cells and those stimulated by gut DC in vitro express β7 by 
default, but that a gut-homing profile is conferred by loss of skin-homing markers (32). 
Our previous study demonstrated blood DC from UC patients have an enhanced ability 
to generate skin-homing T-cells (34). Taken together, these data demonstrate 
dysregulated DC function in UC occurs systemically and not just at intestinal sites. 
Furthermore, these data provide a potential explanation for the occurrence of infiltrating 
gut-homing T-cells at intestinal sites in IBD, yet the propensity of these patients to 
develop cutaneous manifestations of IBD (35). The enhanced ability of DC from the UC 
gut to generate IL-4 producing T-cells, with a loss of IFNγ, supports evidence of UC 
being a Th2-dominated disease (8) but implicates DC as the main drivers of 
dysregulated T-cell responses in UC. The loss of IL-22 production by T-cells stimulated 
by gut DC in UC has implications for reduced epithelial barrier maintenance and repair 
(48), a process which is dysfunctional in UC and can ultimately lead to bacterial 
translocation (41). 
 
This study suggest that luminal bacteria may directly or indirectly modulate intestinal DC 
function to contribute to intestinal immune homeostasis, and that the beneficial effects 
of probiotic strains in IBD (13;14;28;36;43) may be at least partially mediated by gut DC. 
In this case, immunomodulation of gut DC by probiotic LcS in vitro had 
immunoregulatory effects on T-cell responses generated. The restricted stimulatory 
capacity of DC for T-cells in UC was partially restored via LcS conditioning of gut DC. 
LcS also restored the ability of DC in UC to generate T-cells expressing skin-homing 
marker CLA and producing IL-22, with implications in vivo for reduced generation of 
pathogenic gut-specific T-cell responses, and epithelial barrier repair. These data 
support murine studies in which Lactobacillus ameliorated symptoms of colitis in mice in 
an IL-22 dependent fashion (54).  
 
In summary, our data demonstrate alterations in human intestinal DC in UC that drive 
aberrant T-cell responses skewed towards a Th2 profile, with an abnormal homing 
profile, and loss of cytokines involved in epithelial barrier maintenance. These data 
provide evidence that bacteria can modulate human intestinal DC function, generating a 
knock on effect on T-cell responses. Understanding mechanisms by which gut DC drive 
T-cell responses in IBD, and how these T-cell responses contribute to inflammation and 
pathology is of critical importance for determining how the intestinal immune system 
responds inappropriately to the commensal microbiota. Manipulation of the composition 
of the gut microbiota may be beneficial in IBD; however details of which bacterial strains 
confer health benefits are only slowly being defined. Furthermore, recent evidence 
suggests some probiotic strains may even be harmful for use in inflammatory conditions 
(56). DC, which are so pivotal in early bacterial recognition, tolerance induction, and 
shaping T-cell responses, are central to immunomodulation by probiotic bacteria and 
the commensal microbiota. Manipulation of DC to allow generation of DC-specific 
therapy may be beneficial in IBD and would provide novel therapeutic opportunities, 
minimising systemic side effects and immunosuppression.  
 
 































































































































Figure 1. Loss of CD103+CCR7+ DC from the UC colon and infiltrating CD11c- DC. 
a) FACS dot plots demonstrating identification of human intestinal DC according to 
forward scatter versus side scatter, and subsequent gating strategy to select HLA-
DR+Lineage cocktail (CD3/CD14/CD16/CD19/CD34)- cells. b) FACS dot plots showing 
examples of CD103/CCR7 co-expression on gut DC (regions set based on isotype 
controls) and summary graph demonstrating proportions of intestinal DC co-expressing 
CD103 and CCR7 from biopsies obtained from healthy controls (n=10), inflamed UC 
colon (n=7) and non-inflamed UC colon (n=7). T-test (control versus UC) or paired T-
test (inflamed UC versus non-inflamed UC) was carried out: *p<0.05, ***p<0.001. c) 
FACS histograms showing examples of CD11c expression (regions sets using isotype 
controls) and summary graph demonstrating proportions of CD11c- (non-myeloid) 
intestinal DC from biopsies obtained from healthy controls (n=14), inflamed UC colon 
(n=10) and non-inflamed UC colon (n=10). T-test (control versus UC) or paired T-test 
(inflamed UC versus non-inflamed UC) was carried out: **p<0.01, ***p<0.001. 
 
Figure 2. Enhanced TLR2 and TLR4 expression on intestinal DC in UC and 
reduction of TLR expression with LcS conditioning.  
FACS histograms showing examples of TLR2 and TLR4 expression (regions set using 
isotype controls) and summary graphs demonstrating proportions of intestinal DC 
expressing TLR2 and TLR4 from biopsies obtained from healthy controls (TLR2: n=11; 
TLR4: n=11), and inflamed UC +/- LcS (TLR2: n=9; TLR4: n=9). T-test (control versus 
UC) or paired T-test (inflamed UC +/- LcS) was carried out: *p<0.05. 
. 
Figure 3. Reduced T-cell stimulatory capacity of intestinal DC in UC and partial 
restoration with LcS conditioning. 
a) FACS plots showing identification of dividing T-cells post DC stimulation in MLR, via 
gating on blasting lymphocytes according to forward scatter versus side scatter plots 
and subsequent selection of CD3+CFSElo cells. T-cells were sorted as CD4+ naive 
(CD45RO-) T-cells, and CFSE labelled pre-culture. b) Summary graph demonstrating 
proportions of (the same pool of) dividing T-cells stimulated by either control DC (n=5) 
or DC from the inflamed UC colon +/-LcS (n=5). T-cells were stimulated at DC doses of 
0%, 1%, 2% and 3% of the number of T-cells in both cases. Repeated measures two-
way ANOVA was carried out: UC DC were significantly less stimulatory for T-cells than 
control DC, at 3% (**p<0.01), LcS conditioned UC DC were significantly more 
stimulatory than UC DC at 3% (*p<0.05). 
 
Figure 4. Altered imprinting of homing molecules on T-cells by intestinal DC in 
UC and effects of LcS conditioning 
FACS histograms demonstrating examples of stimulated T-cells expressing tissue-
specific homing markers and summary graphs demonstrating proportions of (the same 
pool of) dividing T-cells expressing a) gut-homing markers β7 and CCR9, and  b) skin-
homing markers CLA and CCR4, following stimulation by either control DC (n=5) or DC 
from the inflamed UC colon +/- LcS (n=5), at a DC concentration of 3% (of total T-cells). 
Paired T-test was carried out (*p<0.05, **p<0.01).  































































Figure 5. Intestinal DC alter T-cell production of cytokines in UC and LcS 
restoration of DC ability to induce T-cell IL-22 production 
a) Summary graph demonstrating proportions of (the same pool of) dividing T-cells 
producing cytokines IL-10, IL-4, TGFβ, IFNγ, IL-17 and IL-22 following stimulation by 
either control DC (n=5) or DC from the inflamed UC colon (n=5), at a DC concentration 
of 3% (of total T-cells). Paired T-test was carried out (*p<0.05). b) Summary graph 
demonstrating proportions of (the same pool of) dividing T-cells producing cytokines IL-
10, IL-4, TGFβ, IFNγ, IL-17 and IL-22 following stimulation by DC from the inflamed UC 
colon +/- LcS (n=5), at a DC concentration of 3% (of total T-cells). Paired T-test was 
carried out (*p<0.05). 
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